{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Cancer&page=26", "query": { "condition": "Neuroendocrine Cancer", "page": 26 }, "page_size": 10 }, "pagination": { "page": 26, "page_size": 10, "total_count": 2742, "total_pages": 275, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Cancer&page=27&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Cancer&page=25&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-23T20:41:08.384Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02288897", "title": "PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cutaneous Melanoma" ], "interventions": [ { "name": "PV-10 (10% rose bengal disodium)", "type": "DRUG" }, { "name": "Dacarbazine, temozolomide or talimogene laherparepvec", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Provectus Biopharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2015-04", "completion_date": "2019-09", "has_results": true, "last_update_posted_date": "2022-01-19", "last_synced_at": "2026-10-23T20:41:08.384Z", "location_count": 12, "location_summary": "San Diego, California • Miami Beach, Florida • Tampa, Florida + 9 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT02288897" }, { "nct_id": "NCT01880749", "title": "Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Neurofibromatosis Type 2", "Vestibular Schwannomas", "Meningiomas" ], "interventions": [ { "name": "RAD001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2013-06", "completion_date": "2019-12", "has_results": false, "last_update_posted_date": "2020-05-13", "last_synced_at": "2026-10-23T20:41:08.384Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01880749" }, { "nct_id": "NCT01970358", "title": "A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Poly-ICLC", "type": "BIOLOGICAL" }, { "name": "Peptides", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Patrick Ott, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2014-04", "completion_date": "2018-06", "has_results": true, "last_update_posted_date": "2025-12-29", "last_synced_at": "2026-10-23T20:41:08.384Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01970358" }, { "nct_id": "NCT02332668", "title": "A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Lymphoma", "Solid Tumor", "Classical Hodgkin Lymphoma", "Microsatellite-instability-high Solid Tumor" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Months to 17 Years" }, "enrollment_count": 370, "start_date": "2015-03-19", "completion_date": "2028-02-02", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-10-23T20:41:08.384Z", "location_count": 7, "location_summary": "Aurora, Colorado • Chicago, Illinois • Boston, Massachusetts + 4 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Fargo", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02332668" }, { "nct_id": "NCT02431676", "title": "Survivorship Promotion In Reducing IGF-1 Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Prostate Cancer", "Lung Cancer", "Colon Cancer", "Melanoma of Skin", "Endometrial Cancer", "Liver Cancer", "Pancreatic Cancer", "Rectal Cancer", "Kidney Cancer", "Other Solid Malignant Tumors" ], "interventions": [ { "name": "Metformin", "type": "DRUG" }, { "name": "Coach Directed Behavioral Weight Loss", "type": "BEHAVIORAL" }, { "name": "Self-control weight loss", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 121, "start_date": "2015-05", "completion_date": "2018-12", "has_results": true, "last_update_posted_date": "2024-08-28", "last_synced_at": "2026-10-23T20:41:08.384Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02431676" }, { "nct_id": "NCT02811718", "title": "Resiliency Training for Patients With NF2 Via Videoconferencing With Skype", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Neurofibromatosis 2" ], "interventions": [ { "name": "Stress Management Group 1", "type": "BEHAVIORAL" }, { "name": "Stress Management Group 2", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2016-07", "completion_date": "2018-07", "has_results": false, "last_update_posted_date": "2018-08-17", "last_synced_at": "2026-10-23T20:41:08.384Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02811718" }, { "nct_id": "NCT01121718", "title": "NIR-Guided Sentinel Lymph Node Mapping in Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "ICG Intervention", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2010-09", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2017-02-03", "last_synced_at": "2026-10-23T20:41:08.384Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01121718" }, { "nct_id": "NCT00912418", "title": "Pilot Study for the Evaluation of the Efficacy of Vaccination With Autologous Tumor Cells Plus Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) - in - Adjuvant, Followed by Systemic Low-dose-interleukin-2 (IL-2) Administration, in Patients With High Risk Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "autologous tumor cells plus GM-CSF-in Adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Craig L Slingluff, Jr", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 14, "start_date": "2000-05-01", "completion_date": "2002-10-09", "has_results": false, "last_update_posted_date": "2020-03-02", "last_synced_at": "2026-10-23T20:41:08.384Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00912418" }, { "nct_id": "NCT00111007", "title": "A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Sorafenib (Nexavar, BAY43-9006)", "type": "DRUG" }, { "name": "Carboplatin/Paclitaxel", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 270, "start_date": "2005-05", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2014-10-31", "last_synced_at": "2026-10-23T20:41:08.384Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00111007" }, { "nct_id": "NCT07444606", "title": "Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "DNX-2401", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2026-08-31", "completion_date": "2029-01-30", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-10-23T20:41:08.384Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07444606" } ] }